Epilepsy Articles – February 2020

“Deloitte Access Economics” in Australia was commissioned to write a report on the economic burden of epilepsy in Australia, 2019-2020.

According to the report there are an estimated 142,740 people living with active epilepsy in Australia, costing a total of $12.3 billion.

The report is an interesting read as it looks at the costs of healthcare, informal care, equipment, transport, loss of wellbeing and ‘deadweight losses.’ The estimated costs are comparable to many health conditions especially with Parkinson’s. It would be interesting to see a similar study done in New Zealand.
There are six interesting scientific articles on cannabinoids which you may be interested in reading here.

a) The source of cannabinoids, what is available, what is used and where does it come from?

b) The adverse effects of cannabinoids

c) The role of cannabinoids in epilepsy treatment

d) Pharmacology and drug interactions of cannabinoids

e) The long-term effects of cannabinoids on development behaviour

f) The proposed mechanisms of action of CBD in epilepsy